Financials data is unavailable for this security.
View more
Year on year Halozyme Therapeutics Inc grew revenues 25.62% from 660.12m to 829.25m while net income improved 39.31% from 202.13m to 281.59m.
Gross margin | 82.09% |
---|---|
Net profit margin | 41.43% |
Operating margin | 50.35% |
Return on assets | 19.57% |
---|---|
Return on equity | 111.83% |
Return on investment | 20.73% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Halozyme Therapeutics Inc fell by 116.33m. However, the company earned 388.57m from its operations for a Cash Flow Margin of 46.86%. In addition the company used 96.91m on investing activities and also paid 407.99m in financing cash flows.
Cash flow per share | 3.65 |
---|---|
Price/Cash flow per share | 16.00 |
Book value per share | 3.56 |
---|---|
Tangible book value per share | -3.02 |
More ▼
Balance sheet in USDView more
Current ratio | 10.36 |
---|---|
Quick ratio | 9.15 |
Total debt/total equity | 3.32 |
---|---|
Total debt/total capital | 0.7687 |
More ▼